Thrombolysis for central retinal artery occlusion

Area of Science:

• Ophthalmology
• Vascular Neurology
• Emergency Medicine

Background:

• Central retinal artery occlusion (CRAO) is a leading cause of profound and permanent vision impairment.
• Established conservative treatments for acute CRAO have historically lacked proven therapeutic benefit.
• Thrombolytic therapy has emerged as a potential intervention over the last two decades.

Purpose of the Study:

• To evaluate the efficacy and safety of thrombolytic agents in managing acute central retinal artery occlusion.
• To address the uncertainty surrounding the benefits of thrombolytic treatment due to the retrospective nature of previous studies.

Main Methods:

• Review of existing literature on conservative and thrombolytic treatments for CRAO.
• Analysis of retrospective, uncontrolled studies investigating thrombolytic agents (intravenous and intra-arterial).
• Anticipation of results from an ongoing prospective, controlled clinical trial in Europe.

Main Results:

• The efficacy of traditional conservative treatments for acute CRAO remains unproven.
• Existing studies on thrombolytic therapy for CRAO are predominantly retrospective and uncontrolled, limiting definitive conclusions on its benefit.
• A European prospective controlled clinical trial is underway to provide more reliable data.

Conclusions:

• The true benefit of thrombolytic treatment for CRAO is currently uncertain due to limited high-quality evidence.
• The ongoing European clinical trial is expected to yield more definitive information on the efficacy of thrombolysis.
• Widespread adoption of thrombolytic therapy for CRAO will likely depend on demonstrating rapid deployment post-event, even if efficacy is proven.